OnKure, Pfizer collaborate to evaluate combination of OKI-179 and binimetinib
Activating NRAS mutations occur in approximately 20% of melanomas, representing the second most common oncogenic driver mutation in melanoma after BRAF mutations. An unmet medical need remains for